The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Towards a personalized treatment approach for SCD
Raffaella Colombatti, MD, PhD, University of Padova, Padova, Italy, discusses personalized treatment in sickle cell disease (SCD), highlighting the importance of better understanding the biology of SCD and of finding novel biomarkers to eventually allow patients to achieve a quality of life (QoL) comparable to that of healthy individuals. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
